Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial
Autore:
Anghelescu, I; Szegedi, A; Schlegel, S; Weigmann, H; Hiemke, C; Wetzel, H;
Indirizzi:
Univ Mainz, Dept Psychiat, D-55131 Mainz, Germany Univ Mainz Mainz Germany D-55131 , Dept Psychiat, D-55131 Mainz, Germany
Titolo Testata:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
fascicolo: 4, volume: 8, anno: 1998,
pagine: 315 - 320
SICI:
0924-977X(199812)8:4<315:CTWCAP>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; DOUBLE-BLIND; SERUM LEVELS; FLUVOXAMINE; AKATHISIA; AMITRIPTYLINE; NORCLOZAPINE; METABOLITES; PREVALENCE; EFFICACY;
Keywords:
clozapine; paroxetine; interactions; schizophrenia; side effects;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Anghelescu, I Univ Mainz, Dept Psychiat, Untere Zahlbacher Str 8, D-55131 Mainz, Germany Univ Mainz Untere Zahlbacher Str 8 Mainz Germany D-55131 ny
Citazione:
I. Anghelescu et al., "Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial", EUR NEUROPS, 8(4), 1998, pp. 315-320

Abstract

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs),while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psychopathological outcome was evaluated. A total of 14patients suffering from schizophrenia or schizodepressive disorder with predominant negative symptomatology were included. The duration of the study was at least 6 weeks for each patient. Initial treatment was a monotherapy with clozapine at a daily dose of 2.5 mg/kg weight. After two measurements of serum concentrations of clozapine and metabolites during steady state conditions, an add-on therapy with 20 mg paroxetine was initiated. No concomitant medication was allowed. The main finding of our prospective study was that addition of paroxetine to a monotherapy with clozapine was a well tolerated medication that did not give rise to new clinically relevant side effects. After addition of paroxetine the serum concentrations of clozapine and its major metabolites remained virtually constant. The results of the psychopathological measurements indicated a further clinical improvement, although the small open study could not test for efficacy. (C) 1998 Elsevier Science B.V./ECNP. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 14:40:20